Retrospective analysis of acute ischemic stroke shows timing of antidepressant use associated with short-term recovery and functional independence at 90-days
Restricted accessResearch articleFirst published online June 28, 2024
Retrospective analysis of acute ischemic stroke shows timing of antidepressant use associated with short-term recovery and functional independence at 90-days
Little is known about how the timing of antidepressant use influences stroke outcomes. Previous research shows conflicting results on the impact of a new antidepressant prescription on stroke recovery.
OBJECTIVE:
The objective of this exploratory, retrospective analysis is to examine stroke outcomes by timing of antidepressant use among patients who received stroke treatment.
METHODS:
12,590 eligible patients were treated for a primary or secondary diagnosis of ischemic stroke. The outcome variables were a change in ambulation or modified Rankin scale (mRs) from pre-stroke to discharge; and a change in mRS from pre-stroke to 90-days post-discharge. The independent variable of interest was timing of antidepressant treatment. Logistic regression with generalized estimating equations was used, controlling for covariates.
RESULTS:
Our model predicted that a new antidepressant prescription at discharge was associated with a ∼7% decrease in the likelihood of returning to baseline functional independence at 90-days compared to patients currently using an antidepressant (AOR:0.510, CI:0.277–0.938, p = 0.03).
CONCLUSION:
These results suggest that use of antidepressants was associated with stroke recovery, but the effects are moderated by sex. Further study is needed to determine if this relationship is causal and the mechanisms between timing of antidepressant treatment and outcomes.
AFFINITY Trial Collaboration. (2020). Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): A randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 19(8), 651–660. https://doi.org/10.1016/S1474-4422(20)30207-6
2.
Akyea,R. K., Vinogradova,Y., Qureshi,N., Patel,R. S., Kontopantelis,E., Ntaios,G., Asselbergs,F. W., Kai,J., Weng,S. F. (2021). Sex, Age, and Socioeconomic Differences in Nonfatal Stroke Incidence and Subsequent Major Adverse Outcomes. Stroke, 52(2), 396–405. https://doi.org/10.1161/STROKEAHA.120.031659
3.
Banasr,M., Soumier,A., Hery,M., Mocaër,E., Daszuta,A. (2006). Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biological Psychiatry, 59(11), 1087–1096. https://doi.org/10.1016/j.biopsych.2005.11.025
4.
Barugh,A. J., Gray,P., Shenkin,S. D., MacLullich,A. M. J., Mead,G. E. (2014). Cortisol levels and the severity and outcomes of acute stroke: A systematic review. Journal of Neurology, 261(3), 533–545. https://doi.org/10.1007/s00415-013-7231-5
5.
Brody,D. J., Gu,Q. (2020). Antidepressant Use Among Adults: United States. NCHS Data Brief, 377, 1–8.
6.
Brown,A. F., Liang,L.-J., Vassar,S. D., Merkin,S. S., Longstreth,W. T., Ovbiagele,B., Yan,T., Escarce,J. J. (2013). Neighborhood socioeconomic disadvantage and mortality after stroke. Neurology, 80(6), 520–527. https://doi.org/10.1212/WNL.0b013e31828154ae
7.
Chollet,F., Tardy,J., Albucher,J.-F., Thalamas,C., Berard,E., Lamy,C., Bejot,Y., Deltour,S., Jaillard,A., Niclot,P., Guillon,B., Moulin,T., Marque,P., Pariente,J., Arnaud,C., Loubinoux,I. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): A randomised placebo-controlled trial. The Lancet. Neurology, 10(2), 123–130. https://doi.org/10.1016/S1474-4422(10)70314-8
8.
Commons,K. G., Linnros,S. E. (2019). Delayed Antidepressant Efficacy and the Desensitization Hypothesis. ACS Chemical Neuroscience, 10(7), 3048–3052. https://doi.org/10.1021/acschemneuro.8b00698
9.
Degli Esposti,L., Piccinni,C., Sangiorgi,D., Fagiolini,A., Buda,S. (2015). Patterns of antidepressant use in Italy: Therapy duration, adherence and switching. Clinical Drug Investigation, 35(11), 735–742. https://doi.org/10.1007/s40261-015-0332-4
10.
Etherton,M. R., Shah,S., Haolin,X., Xian,Y., Maisch,L., Hannah,D., Lindholm,B., Lytle,B., Thomas,L., Smith,E. E., Fonarow,G. C., Schwamm,L. H., Bhatt,D. L., Hernandez,A. F., O’Brien,E. C. (2021). Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology, 6(3). https://doi.org/10.1136/svn-2020-000691
11.
FOCUS Trial Collaboration. (2019). Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): A pragmatic, double-blind, randomised, controlled trial. Lancet (London, England), 393(10168), 265–274. https://doi.org/10.1016/S0140-6736(18)32823-X.
12.
Jain,F. A., Connolly,C. G., Reus,V. I., Meyerhoff,D. J., Yang,T. T., Mellon,S. H., Mackin,S., Hough,C. M., Morford,A., Wolkowitz,O. M. (2019). Cortisol, moderated by age, is associated with antidepressant treatment outcome and memory improvement in Major Depressive Disorder: A retrospective analysis. Psychoneuroendocrinology, 109, 104386. https://doi.org/10.1016/j.psyneuen.2019.104386
13.
Kalbouneh,H. M., Toubasi,A. A., Albustanji,F. H., Obaid,Y. Y., Al-Harasis,L. M. (2022). Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 11(13), e025868. https://doi.org/10.1161/JAHA.122.025868
14.
Krivoy,A., Balicer,R. D., Feldman,B., Hoshen,M., Zalsman,G., Weizman,A., Shoval,G. (2015). The impact of age and gender on adherence to antidepressants: A 4-year population-based cohort study. Psychopharmacology, 232(18), 3385–3390. https://doi.org/10.1007/s00213-015-3988-9
15.
Kudlow,P. A., McIntyre,R. S., Lam,R. W. (2014). Early switching strategies in antidepressant non-responders: Current evidence and future research directions. CNS Drugs, 28(7), 601–609. https://doi.org/10.1007/s40263-014-0171-5
16.
Kwon,K.-E., Yang,B. R., Kim,M.-S., Park,B.-J., Lee,J., Jung,S.-Y. (2023). Antidepressants and the Risk of Ischemic Stroke in Older Adults According to the Degree of Serotonin Reuptake Inhibition: A Retrospective Cohort Study. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 31(12), 1164–1177. https://doi.org/10.1016/j.jag2023.07.013
17.
Larsen,M. H., Rosenbrock,H., Sams-Dodd,F., Mikkelsen,J. D. (2007). Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. European Journal of Pharmacology, 555(2-3), 115–121. https://doi.org/10.1016/j.ejphar.2006.10.029
18.
Legg,L. A., Tilney,R., Hsieh,C.-F., Wu,S., Lundström,E., Rudberg,A.-S., Kutlubaev,M. A., Dennis,M., Soleimani,B., Barugh,A., Hackett,M. L., Hankey,G. J., Mead,G. E. (2019). Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. The Cochrane Database of Systematic Reviews, 2019(11), CD009286. https://doi.org/10.1002/14651858.CD009286.pub3
19.
Lim,C.-M., Kim,S.-W., Park,J.-Y., Kim,C., Yoon,S. H., Lee,J.-K. (2009). Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research, 87(4), 1037–1045. https://doi.org/10.1002/jnr.21899
20.
Lundström,E., Isaksson,E., Näsman,P., Wester,P., Mårtensson,B., Norrving,B., Wallén,H., Borg,J., Dennis,M., Mead,G., Hankey,G. J., Hackett,M. L., Sunnerhagen,K. S., EFFECTS Trial Collaboration. (2020). Update on the EFFECTS study of fluoxetine for stroke recovery: A randomised controlled trial in Sweden. Trials, 21(1), 233. https://doi.org/10.1186/s13063-020-4124-7
21.
McCann,S. K., Irvine,C., Mead,G. E., Sena,E. S., Currie,G. L., Egan,K. E., Macleod,M. R., Howells,D. W. (2014). Efficacy of antidepressants in animal models of ischemic stroke: A systematic review and meta-analysis. Stroke, 45(10), 3055–3063. https://doi.org/10.1161/STROKEAHA.114.006304
22.
Mead,G. E., Hsieh,C.-F., Lee,R., Kutlubaev,M. A., Claxton,A., Hankey,G. J., Hackett,M. L. (2012). Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. The Cochrane Database of Systematic Reviews, 11(11), CD009286. https://doi.org/10.1002/14651858.CD009286.pub2
23.
Mead,G., Graham,C., Lundström,E., Hankey,G. J., Hackett,M. L., Billot,L., Näsman,P., Forbes,J., Dennis,M. (2024). Individual patient data meta-analysis of the effects of fluoxetine on functional outcomes after acute stroke. International Journal of Stroke: Official Journal of the International Stroke Society, 17474930241242628. https://doi.org/10.1177/17474930241242628
24.
Miedema,I., Horvath,K. M., Uyttenboogaart,M., Koopman,K., Lahr,M. M. H., De Keyser,J., Luijckx,G. J. (2010). Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA. Journal of the Neurological Sciences, 293(1-2), 65–67. https://doi.org/10.1016/j.jns.2010.03.004
25.
Mortensen,J. K., Larsson,H., Johnsen,S. P., Andersen,G. (2014). Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. Stroke, 45(7), 2121–2123. https://doi.org/10.1161/STROKEAHA.114.005302
26.
Niaz,D., Necyk,C., Simpson,S. H. (2021). Depression and antecedent medication adherence in a cohort of new metformin users. . Diabetic Medicine: A Journal of the British Diabetic Association, 38(2), e14426. https://doi.org/10.1111/dme.14426.
27.
Niaz,D., Necyk,C., Simpson,S. H. (2022). Association Between Antidepressant Use and Adherence to Anti-hyperglycemic Medications in Adults With Type 2 Diabetes and Depression: A Retrospective Cohort Study. Canadian Journal of Diabetes,
S14992671(22)00065X. https://doi.org/10.1016/j.jcjd.2022.03.002
28.
Ozaki,A. F., Choi,A. S., Le,Q. T., Ko,D. T., Han,J. K., Park,S. S., Jackevicius,C. A. (2020). Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circulation. Cardiovascular Quality and Outcomes, 13(3), e005969. https://doi.org/10.1161/CIRCOUTCOMES.119.005969
Schmidt,H. D., Duman,R. S. (2007). The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behavioural Pharmacology, 18(5-6), 391–418. https://doi.org/10.1097/FBP.0b013e3282ee2aa8
31.
Siepmann,T., Kepplinger,J., Zerna,C., Schatz,U., Penzlin,A. I., Pallesen,L.-P., Illigens,B. M.-W., Weidner,K., Reichmann,H., Puetz,V., Bodechtel,U., Barlinn,K. (2015). The Effects of Pretreatment versus De Novo Treatment with Selective Serotonin Reuptake Inhibitors on Short-term Outcome after Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association, 24(8), 1886–1892. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.04.033
32.
Stinear,C. M., Lang,C. E., Zeiler,S., Byblow,W. D. (2020). Advances and challenges in stroke rehabilitation. The Lancet Neurology, 19(4), 348–360. https://doi.org/10.1016/S1474-4422(19)30415-6
33.
Stulberg,E. L., Twardzik,E., Kim,S., Hsu,C.-W., Xu,Y., Clarke,P., Morgenstern,L. B., Lisabeth,L. D. (2021). Association of Neighborhood Socioeconomic Status With Outcomes in Patients Surviving Stroke. Neurology, 96(21), e2599–e2610. https://doi.org/10.1212/WNL.0000000000011988
34.
Trivedi,M. H., Rush,A. J., Wisniewski,S. R., Nierenberg,A. A., Warden,D., Ritz,L., Norquist,G., Howland,R. H., Lebowitz,B., McGrath,P. J., Shores-Wilson,K., Biggs,M. M., Balasubramani,G. K., Fava,M. (2006). Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 163(1), 28–40. https://doi.org/10.1176/appi.aj163.1.28
35.
Yi,J., Lu,J., Yang,A., Marsh,E. B. (2022). In-hospital predictors of post-stroke depression for targeted initiation of Selective Serotonin Reuptake Inhibitors (SSRIs). BMC Psychiatry, 22(1), 722. https://doi.org/10.1186/s12888-022-04378-0
36.
Zhang,J., Gong,Y., Zhao,Y., Jiang,N., Wang,J., Yin,X. (2021). Post-stroke medication adherence and persistence rates: A meta-analysis of observational studies. Journal of Neurology, 268(6), 2090–2098. https://doi.org/10.1007/s00415-019-09660-y
